Clinical trials: Dyslipidaemia
- Condition Dyslipidaemia
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386
- Trial name
- NCT04694989
- Testing
- CKD-386, D013, D326, D337
- Where
- South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypercholesterolemia, Dyslipidemias
A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
This Phase 1 study has been designed to evaluate the absolute bioavailability of PF-04950615 (RN316) in subjects with hypercholesterolemia who are not currently on lipid-lowering therapy.
- Conditions
- Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders
- Trial name
- NCT01435382
- Testing
- PF-04950615 (RN316)
- Where
- 7 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesteremia
Effects of Limicol on LDL-cholesterol
The principal objective of this study is to investigate the effects of a novel food supplement (Limicol) on LDL-cholesterol levels in healthy subjects with moderate hypercholesterolemia.
- Trial name
- NCT01354327
- Testing
- Limicol
- Where
- France
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Lescuyer Laboratory
Dyslipidemia
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination…
- Trial name
- NCT05787002
- Testing
- AZD0780, Rosuvastatin
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypercholesterolemia, Cardiovascular Risk Factor
Effects of 6 Weeks TOTUM-070 on Lipid Metabolism and Cardiovascular Health in Individuals at Increased Cardio-metabolic Risk
This clinical study aims to assess the efficacy of 6 weeks 2.5g dose of TOTUM-070, a mix of 5 plant extracts, on lipid metabolism and cardiovascular health in individuals at increased cardio-metabolic risk.
- Conditions
- Hypercholesterolemia, Cardiovascular Risk Factor, Dyslipidemias, Atherosclerosis
- Trial name
- OLALIP (NCT05594979)
- Testing
- TOTUM-070
- Where
- France
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Valbiotis
LDL Cholesterol, Triglycerides
Safety and Efficacy of a Natural Health Product in Reducing Cholesterol and Triglyceride Levels.
The purpose of this study is to assess the safety and efficacy of a natural health product among participants with elevated LDL cholesterol and triglyceride levels.
- Trial name
- NCT01028274
- Testing
- Investigational Product 1, Investigational Product 2
- Where
- Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Nordic Pharma, USA
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
An open-label, randomized, single-dose, 2X3X3 partial replicate, crossover study to compare the pharmacokinetics and safety between a fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a fixed…
- Trial name
- NCT02995720
- Testing
- Fimasartan/Amlodipine combination drug, Rosuvastatin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Healthy Adult Male and Female Volunteers, Mild Dyslipidemia
EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions.
- Trial name
- NCT07412080
- Testing
- EDP167
- Where
- 2 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eddingpharm (Zhuhai) Co., Ltd.
Metabolic Disorders, Non-alcoholic Steatohepatitis
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in…
- Trial name
- NCT04142424
- Testing
- AZD2693
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2 weeks of dosing of PF-06427878 in…
- Trial name
- NCT02855177
- Testing
- PF-06427878
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertension, Hyperlipidemia
CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)
The purpose of this study is to evaluate the drug-drug interaction of CKD-346(Telmisartan/S-Amlodipine, Rosuvastatin)
- Trial name
- NCT02047175
- Testing
- Telmisartan/S-Amlodipine, Rosuvastatin, Telmisartan/S-Amlodipine + Rosuvastatin
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypercholesterolemia
Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
This study is designed to measure the effects of LGT209 when given intravenously to patients with high cholesterol who are on stable doses of statin medications, and to healthy subjects with elevated cholesterol
- Trial name
- NCT01979601
- Testing
- LGT209
- Where
- 2 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy
A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers. Primary Objectives: 1.
- Trial name
- NCT00776841
- Testing
- Aramchol
- Where
- Israel
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Galmed Medical Reserch
Dyslipidemias
Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)
The purpose of this Phase 1 clinical study is to evaluate the safety and tolerability of a single dose of BSA204 injection in Chinese adults with borderline high levels of lipoprotein(a) [Lp(a)].
- Trial name
- NCT07551505
- Testing
- BSA204
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bisirna Therapeutics (Suzhou) Co., Ltd.
Hypertriglyceridemia
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
This study is intended to evaluate the potential 2-way reciprocal interaction between multiple doses of Epanova™ and a single dose of rosuvastatin
- Trial name
- ECLIPSEIII (NCT02859129)
- Testing
- rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Mild Dyslipidemia
A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia
This Phase 1, double-blind (sponsor open) study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 given to subjects with mild dyslipidemia.
- Trial name
- NCT01105598
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Esperion Therapeutics, Inc.
Fed
Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions
This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding…
- Trial name
- NCT01827878
- Testing
- Lisinopril and Hydrochlorothiazide Tablets (20+25) mg, Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- IPCA Laboratories Ltd.
Cardiovascular Diseases
Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America
Post-Marketing Observational study of Niaspan® tablet in accordance with each country regulations. This study will be conducted in a prospective, single-arm, multi-center format.
- Trial name
- NCT01200160
- Testing
- Niacin
- Where
- 22 sites in Colombia, Mexico and 1 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Abbott
Overweight, Elevated Cholesterol
Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man
This observational placebo-controlled pilot study is intended to document whether or not Lyzme5, an over-the-counter (OTC) proprietary nutritional supplement product can positively impact, (a) weight and, (b) cholesterol levels…
- Trial name
- Lyzme5 (NCT01634646)
- Testing
- Lyzme5
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Jeff Golini
Dyslipidaemia
Study of the Electrocardiographic Effects of TA-8995
A study in healthy males and females to see if a high single dose of TA-8995 has an effect on the ECG QTcF interval.
- Trial name
- NCT02241759
- Testing
- TA-8995, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Xention Ltd